n INTRODUCTION P atients affected by chronic inflammatory rheumatism are at greater risk of infection compared with the general population, because of the disease and its effects on the immune system, and the use of drugs that interfere with the immune system (1). Among these latter, mention must be made of steroids, synthetic disease modifying antirheumatic drugs (DMARDs) and biological DMARDs. The latter are increasingly used against rheumatism, and often in association with synthetic DMARDs and/or steroids. Great efficacy has been seen in the treatment of certain diseases, with acceptable risk levels, but the greatest danger is the possibility that patients in therapy develop new infections or see latent infections breaking out. Several studies exist in the literature on the reactivation of tuberculosis, hepatitis, and opportunistic infections in patients undergoing bio-technological therapy (2), whereas we found very few reports concerning the effect of influenza virus in patients treated with immunomodulatory drugs. The latter mostly affect anti-influenza vaccinations in patients being treated with biological drugs, and an increase in antibodies has been seen; there is an immunosufficient response to guarantee pro-summary This study aimed to evaluate the incidence of influenza-like illness (ILI), from October 2009 to May 2010, in a group of patients suffering from chronic inflammatory rheumatism and treated with biological therapies. At the end of 2009-2010 influenza season, 159 patients under biological therapies answered to a questionnaire distributed 8 months before and were deeply interviewed. The group included 69 men and 90 women (mean age 47.6); 49 suffering from rheumatoid arthritis, 61 with psoriatic arthritis, 32 with ankylosing spondylitis and 17 with other spondyloarthritis; 146 patients were treated with anti-TNF-α, 7 with rituximab and 6 with abatacept; 128 patients assumed DMARDs and 72 patients assumed low dose of steroids. A case of ILI was identified by anamnestic findings and according to the case definitions commonly used in Europe. 17% of the considered population reported at least one episode of ILI during the monitoring period; none of the patients during the acute influenza attack suffered particularly severe symptoms and no one was hospitalized due to complications. Despite the diversity among the considered subgroups, the statistical analysis did not show any significant difference when incidence of ILI was considered for different disease, different biological agent and different association therapy. None of the examined variables resulted statistically significant concerning the relative risk evaluation. The incidence of ILI into a cohort of 159 patients treated with biological agents during the influenza season 2009-2010 resulted higher than the value reported in a wide sample of Italian population in the same period. However, the pandemic impact was not heavy among the studied patients, considering that no important complications or hospitalizations have been reported.
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original article tection, although it is often less than in the control group; vaccination does not seem to worsen the disease, and there do not appear to be serious side effects in these patients (3) (4) (5) . Additionally, EULAR recommendations for the vaccination of patients with auto-immune inflammatory rheumatism suggest giving these patients the influenza vaccination (6) . Pneumonia is the most common serious complication of influenza, and is one of the greatest causes of death in patients with rheumatoid arthritis (7, 8) . The influenza virus is one of the most frequent causes of Community Acquired Pneumonia (CAP, infection of the lungs that affect individuals who have not recently been hospitalized), accounting for up to 22% of the cases examined (9, 10) . The mortality rate for influenza-related CAP was 4.4% in a recent, wide-ranging study in Germany (11). The incidence of bacterial or viral pneumonia, in a US study on 16,000 patients undergoing pharmacological treatment for rheumatoid arthritis and then monitored for 3.5 years showed 17 cases/1000 patients/ year. The same study also showed that treatment with prednisone and leflunomide increased the risk of pneumonia, whereas treatment with salazopirina, metotrexato, etenercept, adalimumab, and infliximab saw no increase in risk levels (12 
n PATIENTS AND METHODS
Towards the end of the 2009-2010 influenza season, 159 patients being treated with biological drugs filled in a questionnaire which had been handed out eight months beforehand with a series of recommendations for the patients receiving immunomodulatory drugs for the new influenza A/ H1N1, and then they were interviewed. A case of ILI was identified by anamnestic finding of acute respiratory affection with brief and sudden onset, with fever ≥38°, followed at least by one symptom among headache, generalized malaise, feeling of fever (sweating, chills), fatigue, accompanied with at least one respiratory symptom among cough, sore throat and nasal congestion. It was also required to the patient to indicate, the number of influenza episodes suffered, the month of onset and the severity of the symptoms. At the same time was requested if it was necessary to discontinue the biological therapy, to assume antibiotics and/or antiviral agents, if it was necessary the hospitalization and if the patient undergone the influenza H1N1 diagnostic test.
Statistical analysis
The incidence of ILI was reported as frequency and rate according to clinical and epidemiological features of patients; the statistical differences among subgroups was evaluated through the χ 2 -test or the Fisher's exact test for small samples, as categorical variables. The risk evaluation was obtained through the calculation of the relative risk (RR) and its statistical significance through the confidence interval (CI) and the p value.
n RESULTS
The group included 69 males and 90 females, aged between 13 and 79 (average 47.6); 49 suffered from rheumatoid arthritis, 61 from psoriatic arthritis, 32 from ankylosing spondylitis, and 17 from other spondyloarthritis (undifferentiated spondyloarthritis, enteropathic arthritis, and reactive arthritis). One hundred forty-six were receiving anti-TNF treatment (51 infliximab, 42 adalimumab, 53 etanercept), 7 with rituximab, and 6 abatacept; 128 were under therapy with DMARDs (118 methotrexate, 7 ciclosporina, 1 leflunomide, 2 salazopirina), and 73 with low-dosage steroids. Thirtyfour had been vaccinated against the seasonal influenza (28 in the previous years), 4 had received antipneumococcal vaccination (4 in the previous years), and 12 had been vaccinated against A/H1N1 influenza (Tab. I). The 53.5% of patients also suffered from comorbidities, which required therapy in 91.8% of cases: 30.2% were suffering from cardiovascular diseases, 13.8% from gastro-intestinal complaints, 6.3% diabetes mellitus, 5% from lung disease, and 2.5% nephropathy. (Fig. 1C) . The incidence considered for different biological agents resulted 13.7% for infliximab, 19% for adalimumab, 16.9% for etanercept, 28.5% for rituximab and 16.6% for abatacept. The incidence of ILI in the group of pa- 
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to the small dimension of the examined samples. None of the patients during the acute influenza attack suffered particularly severe symptoms and no one were hospitalized due to complications; 22.2% of the patients discontinued for few days the biological therapy, 51.8% assumed antibiotics and no one assumed antiviral therapies; none of the patients undergone the influenza H1N1 diagnostic test. None of the examined variables resulted statistically significant concerning the relative risk evaluation (Tab. II).
n DISCUSSION
The incidence of ILI in a cohort of 159 patients under treatment with biological drugs during the 2009-2010 influenza period was 17% ( Fig. 2A) , decidedly higher than the figures seen with a larger sample taken in Italy (2%) at the same time (9.7%) (13, 14) . Considering the absence of hospital admissions and particularly serious symptoms, and the limited number of patients who changed therapy during ILI, the impact of the pandemic can certainly be considered as light among the sample considered by us; the rarity in the literature of reports of the effect of influenza viruses on patients being treated with biotechnological drugs during the pandemic appears in line with this consideration (20, 21) . Discussion in the literature of proof in laboratory animals of the responsibility of TNF-α as a mediator for pulmonary inflammation during viral pneumonia, and the positive effects it has the treatment with anti-TNF on symptoms and anatomopathological lesions in the same animals seems important (22, 23) . Small percentage differences in favour of males and young people (Fig. 1A , B) were original article
Incidence of influenza-like illness into a cohort of patients not statistically significant (p value 0.558 and 0.74). Distribution by disease was not statistically significant either (p value 0.52), whereas a greater incidence was seen among patients affected by ankylosing spondylitis, and lesser incidence in patients with rheumatoid arthritis (Fig. 2B) . ILI was more frequent in patients being treated with rituximab then other biologicals (Fig. 2C) , and less frequent among patients receiving only biologicals than those who took it with DMARDs or steroids, or all three together (Fig. 2D) In spite of the feelings of fear generated by the spread of the pandemic, and notwithstanding the information and advice we gave, only 21.4% of patients were found to have been vaccinated against seasonal influenza, and even fewer against AH1N1 influenza (7.5%) or pneumococcus (2.5%) (Fig. 1D) . In 41 patients who said they had received at least one of these vaccinations, incidence of ILI was 26.8%, against the 13.5% among unvaccinated patients, and the difference was at the limit of statistical significance (p value 0.05); risk assessment also showed that in vaccinated patients the risk of ILI was twice what it was among unvaccinated patients (IRR:1.979), and this variable is at the limit of statistical significance (95% CI:1.002-3.908 and p value 0.049). It was difficult to find a reasonable explanation for this result, and the information from interviews was not completely significative to us, missing of data concerning the functional compromising, the ability to lead a social life, and the type of employment (for example, if the patient worked in situations with a high risk of contagion), the type of family, and incidence of ILI among other family members. We also assessed time differences between giving the vaccine and the onset of ILI among patients vaccinated against seasonal influenza and/or A/H1N1who reported at least one episode of ILI; barely 18.2% reported the onset of ILI during November and December, when the vaccine was given; considering, therefore, that vaccine reaction usually begins 6-12 hours after inoculation, and that more than 80% of patients developed ILI long after taking the vaccine, it appears likely that vaccine reaction did not cause a greater incidence of ILI among vaccinated patients.
In conclusion, we saw that incidence of ILI among patients receiving biotechnological drugs during the 2009-2010 influenza season was greater than in the general population, but that the effects of the pandemic on the group of patients under study were very mild and with no truly serious consequences; nor had many patients been vaccinated, although they had been encouraged to do so. We found no evidence of differences when incidence of ILI was considered for different disease, different biological agent and different association therapy. 
